{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.0","spread":"40.0","value":"422.5"},{"groupId":"OG001","lowerLimit":"32.1","spread":"32.1","value":"403.7"},{"groupId":"OG002","lowerLimit":"66.1","spread":"66.1","value":"616.9"},{"groupId":"OG003","lowerLimit":"87.3","spread":"87.3","value":"603.5"}]}],"title":"Eribulin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.5","spread":"13.5","value":"1812.6"},{"groupId":"OG001","lowerLimit":"36.4","spread":"36.4","value":"3686.1"},{"groupId":"OG002","lowerLimit":"66.1","spread":"66.1","value":"4693.9"},{"groupId":"OG003","lowerLimit":"38.9","spread":"38.9","value":"3633.7"}]}],"title":"Irinotecan"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.7","spread":"19.7","value":"68.00"},{"groupId":"OG001","lowerLimit":"11.6","spread":"11.6","value":"145.04"},{"groupId":"OG002","lowerLimit":"42.2","spread":"42.2","value":"138.22"},{"groupId":"OG003","lowerLimit":"153.2","spread":"153.2","value":"65.47"}]}],"title":"Metabolite SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 20 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG000","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 20 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG001","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 100 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG002","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 100 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 125 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG003","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 125 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included participants who had documented dosing history and at least one post-dosing quantifiable drug concentration.","reportingStatus":"POSTED","timeFrame":"For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)","title":"Phase 1, AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of Eribulin, Irinotecan and Its Active Metabolite SN-38","type":"SECONDARY","unitOfMeasure":"hour*nanogram per milliliter (h*ng/mL)"}